Clinical Trial Update: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating doxorubicin with upfront dexrazoxane for advanced or metastatic soft tissue sarcoma has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Epithelioid Sarcoma
• Fibrosarcoma
• Leiomyosarcoma
• Liposarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Myxofibrosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• DEXRAZOXANE (DEXRAZOXANE)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07